Celregen Therapeutics

Company

Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform

Fineline Cube Mar 19, 2025

Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

Company Drug

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Company

Kelun‑Biotech Reports 2025 Revenue RMB 2.06 Billion – Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification

Company Drug

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China